The Canadian Cancer Society estimates that almost 200,000 Canadians are diagnosed with cancer and 80,000 will die of the disease each year. Approximately 40% of Canadians will be diagnosed with cancer in their lifetime, and 1 in 4 will die from this disease. As a result, there is a compelling need to discover new and improved diagnostic tools to detect cancer earlier and more accurately, and to develop new and more targeted medicines to treat the disease with increased precision and greater efficacy. This is especially true for cancers that have advanced to late stages and for malignancies for which there are currently no adequate treatments including metastatic breast cancer, pancreatic cancer, and ovarian cancer.
The Centre for Pharmaceutical Oncology at the University of Toronto’s Leslie Dan Faculty of Pharmacy aims to bridge the gap between fundamental discoveries in cancer biology and the development of new diagnostics and therapeutics for cancer and their advancement to first-in-humans Phase I/II clinical trials. The Centre will focus its attention and resources on developing treatments and diagnostic tools for breast, pancreatic, and ovarian cancers.
The University of Toronto and its affiliated cancer treatment centres are international leaders in cancer biology research and clinical trials. The Centre for Pharmaceutical Oncology will leverage these existing strengths and world-class infrastructure, and link these two pillars to bolster knowledge and development in pharmaceutical oncology – an area that has tremendous potential to change how we identify and treat cancer globally.
There is an exceptional opportunity for the Centre and its members to improve the outcome of cancer patients around the world. From earlier diagnosis via non-invasive chip-based technologies capable of detecting and identifying cancer in twenty minutes, to exploiting the biology of cancer cells to import molecules that can be triggered to destroy these cells from within, to developing innovative drug delivery systems and personalized treatments for cancer, the pharmaceutical scientists at the Leslie Dan Faculty of Pharmacy are poised to change cancer detection and treatment. As Canada’s leading Faculty of Pharmacy and home to more than 150 graduate students and post-doctoral fellows, the Graduate Department of Pharmaceutical Sciences at the Leslie Dan Faculty of Pharmacy is the largest academic pharmaceutical sciences research program in Canada. Within the Faculty, there is an emerging group of cancer researchers who are conducting cutting edge research in pharmaceutical oncology. The Centre brings together these researchers, their trainees, and other collaborators at the University of Toronto interested in discovering and developing innovative solutions in the fight against cancer.
In addition to conducting groundbreaking and translational research by internationally-recognized leaders in this field, the Centre for Pharmaceutical Oncology will further leverage the strengths of this network of world-class instructors to provide educational offerings through the Faculty’s Doctor of Pharmacy, Pharmaceutical Chemistry Specialist, and graduate (MSc and PhD) programs. As a result, the Centre will provide an excellent collaborative training experience in pharmaceutical oncology for trainee members and play an important role in the development of the next generation of pharmaceutical oncologists.
NEWS: Applications are now available for one year MSc and PhD Scholarships ($4,000 each). Deadline for application is June 29, 2018. Click here for Call for Applications. Click here for CPO Scholarship Application Form.
Interested in joining the Centre for Pharmaceutical Oncology? Click here to complete an application form.
Interested in donating to the Centre for Pharmaceutical Oncology? Click here to learn more.